Emerging Lp(a)-Lowering therapies: Is muvalaplin a potential breakthrough?

Int J Cardiol Cardiovasc Risk Prev. 2024 Mar 26:21:200262. doi: 10.1016/j.ijcrp.2024.200262. eCollection 2024 Jun.

Authors

Zeeshan Afzal¹, Sara Hira², Huili Cao³

Affiliations

¹ Department of Internal Medicine, Shanxi Medical University, China.
² FMH College of Medicine & Dentistry, Lahore, Pakistan.
³ Department of Cardiology, The Second Hospital of Shanxi Medical University, China.

No abstract available

Publication types

Editorial